Studies on the antiobesity action and mechanisms of daidzein derivative:LRXH609

Abstract

Abstract: AIM:To approach the antiobesity action and mechanisms of the daidzein derivative: LRXH609 (LRX). METHODS:The body weight, Lee′s index, total weight of celiac fat tissue, food intake, serum glucose and lipids in obese rats induced by a high-fat diet were measured and the antiobesity action was tested after LRX was administered for 30 days. 3T3-L1 pre-adipocytes were induced by in vitro culture, the effects of LRX on cell proliferation, lipogenesis, lipolysis were observed. RESULTS:The body weight, Lee′s index, fat tissue weight in obese rats were significantly decreased by LRX, and the concentrations of TC, FFA in serum were decreased, the proliferation of 3T3-L1 pre-adipocytes was inhibited, the activities of hormone sensitive lipase in 3T3-L1 pre-adipocytes were significantly elevated, the glycerine release from adipocytes was promoted and the concentrations of TG in adipocytes were decreased. CONCLUSION: LRX plays a role in antiobesity action and regulating blood lipid and the mechanism might be related to inhibiting proliferation and differentiation of pre-adipocytes, stimulating TG decomposition by activating hormone-sensitive lipase and decreasing the TG storage in adipocyte.

Key words: obesity, daidzein, 3T3-L1 pre-adipocyte, hormone-sensitive lipase

CLC Number:

R965. 2

WU Guan-zhong, GUO Yong-qi, SU Xin, YANG Hong-xia, ZHANG Jian. Studies on the antiobesity action and mechanisms of daidzein derivative:LRXH609[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 519-523.

References

[1] Rimbach G, Boesch-Saadatmandi C, Frank J. Dietary isoflavones in the prevention of cardiovascular disease-A molecular perspective[J]. Food Chem Toxicol, 2008, 46 (4): 1308-1319.
[2] Marla SJ, Manzoni MSc, Elizeu A, et al.Fermented soy product supplemented with isoflavones affected fat depots in juvenile rats[J]. Nutrition, 2005, 21 (10): 1018- 1024.
[3] Naaz A, Yellayi S, Zakroczymski MA, et al. The soy isoflavone genistein decreases adipose deposition in mice[J]. Endocrinology, 2003, 144(8): 3315-3320.
[4] 孙志, 张中成, 刘志城.营养性肥胖动物模型的实验研究[J]. 中国药理学通报, 2002, 18(4): 466-467.
[5] Yang JY, Della-Fera MA, Baile CA.Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 Cells[J]. Obesity, 2008, 16(1): 16-22.
[6] Moreno DA, Ilic N, Poulev A.Effects of Arachis hypogaeanutshell extract on lipid metabolic enzymes and obesity parameters[J]. Life Sci, 2006, 78(24): 2797- 2803.
[7] Ahn J, Lee H, Kim S, et al. The anti-obesity effect of quercetin is mediated by the AMPK andMAPK signaling pathways[J]. Biochem Biophys Res Commun, 2008, 373 (4): 545-549.
[8] Moon HS, Lee HG, Choi YJ, et al. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity [J]. Chem Biol Interact, 2007, 167(2): 85-98.
[9] Haemmerle G, Zimmermann R, Zechner R.Letting lipids go: hormone-sensitive lipase [J]. Curr Opin Lipidol, 2003, 14(3): 289-297.
[10] Langin D.Adipose tissue lipolysis as a metabolie pathway to define pharmacological strategies against obesity and the metabolic syndrome[J]. Pharmaeol Res, 2006, 53 (6): 482-491.
[11] Hodsona L, Skeaff CM, Fielding BA.Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake[J]. Prog Lipid Res, 2008, 47 (5): 348-380.

[1]	GUO Yixun, GUAN Xiaoyin, WANG Bo, WEI Yingda, ZHANG Yan, LIN Jianhua. Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 341-346.
[2]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[3]	MA Yitong, MA Jianhong, GAO Yating, LIU Chang. Pathogenic mechanism and research progress of adipocytokines in endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1315-1320.
[4]	YUAN Lijialong, QIN Xuping. ATP synthase beta subunit function and disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 464-470.
[5]	SHEN Ji-zhong, LIU Hang. Experimental study of a metabolic syndrome mouse model induced by high sucrose-containing drinking water [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1011-1015.
[6]	CHEN Zi-miao,WANG Mei-rong,YE Ting-ting,GU Xue-jiang CHEN Xiong, ZHU Hong, NI Lian-song. Antiobesity effect of ketotifen in high-carbon hydrate-fat diet induced obese rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 23-28.
[7]	LIU Jing, SUN Ning-ling, YANG Song-na, MA Zhi-yi, YANG Jing. Effects of orlistat on endothelium-independent vasodilation function in obese subjects with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1061-1064.
[8]	CUI Ming-xia, WANG Lei, ZHANG Bao-lai, LU Li, WANG Li, ZHENG Rong-liang, WUYong-jie. Establishment of diabetic obese rat model and the therapeutic effects of sibutramine on it [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1325-1329.
[9]	LIU Ying-zi, Vural Ozdemir, OUYANG Dong-sheng, LIU Zhao-qian, LIU ie, LI Zhi,WANG Dan, ZENG Fei-yue, TAN Zhi-rong, HU Dong-li, ZHOU Hong-hao. Differential effects of PPARγligand rosiglitazone and selective antagonist GW9662 on adipocytokine gene expression in 3T3-L1 adipocytes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1157-1162.
[10]	PANG Xiao-yi, DONG Zhi, FU Jie-min. Advances in cannabinoid receptor 1 antagonistic effect in obesity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 606-609.
[11]	PANG Xiao-Yun. Soy isoflavones and cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 721-724.
[12]	CHEN Guang-Liang, LI Li, YAN Shang-Xue, HUANG De-Wu. Anti-obesity effect of sibutramine hydrochloride in alimentary obesity rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 55-58.
[13]	WANG Hui, CHEN Bing. Weight relief of sibutramine in treatment of obesity with different body weight [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(4): 327-330.
[14]	WANG Ping-Fang, YANG Ya, LIAO Er-Yuan, YAN Xiang, ZHANG Hong, HE Lin, ZHU Xue-Ping. Effect of sibutramine on the obesity with metabolic disorder of blood glu-cose and lipid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(3): 224-230.
[15]	YU Li-Mei, XU Lu, YAO Ming-Hui. Inhibitory effects of isoflavones on growth of YAC-1 T lymphocyte tumor cells of mice in vitro and ehrlich-ascites-tumor of mice in vivo [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(4): 334-338.